Pfizer Q3 FY26 PAT up 11% to 142 cr; revenue grows about 20% to 645 cr
PFIZER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts more than Nifty Smallcap 250 and 3.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Pfizer posted Q3 FY26 revenue of 645 crore, up 20% YoY. Net profit rose 11% to 142 crore. For 9M FY26, revenue grew 12% to 1,890 crore and PAT rose 20% to 523 crore. The company recorded 58 crore in exceptional items, including 40 crore in personnel separation costs from a Cipla supply and marketing deal for four brands, and 19 crore impact from new Labour Codes. Limited review report by B S R and Co. LLP is clean with no modifications.
Near 20% revenue growth and 11% PAT rise in Q3 are positive. Exceptional charge of 58 cr from Cipla deal and Labour Codes weighs on earnings.